Merck 4Q Revenues: $5.7 billion (flat) 4Q Earnings: $1.1 billion (+2%) FY Revenues: $22 billion (-4%) FY Earnings: $4.6 billion (-20%) Comments: Sales growth of Singulair and Vytorin drove results for the year. Worldwide sales of Singulair reached $819 million for the quarter, up 12% and $3 billion for the year, up 13%. Global sales of Vytorin, developed and marketed by the Merck/Schering-Plough partnership, reached $355 million in the fourth quarter and $1 billion for th...